OralID was developed with the vision to create a simpler, more efficient, and more affordable oral cancer screening device
Forward Science announces an agreement with Aspen Dental Management that makes the OralID enhanced oral cancer screening device available to independent dentists in 830-plus Aspen Dental branded offices.(Credit: Business Wire)
Forward Science announced an agreement with Aspen Dental Management, Inc. (ADMI) that makes the OralID enhanced oral cancer screening device available to independent dentists in 830-plus Aspen Dental branded offices.
The multi-year agreement between Forward Science and ADMI, the dental support organization (DSO) providing practice management and non-clinical support to practitioners in Aspen Dental offices nationwide, offers these dentists state-of-the-art oral cancer screening technology to help with early stage oral cancer discovery that can save lives.
In 2020, data shows that in the U.S. alone, more than 53,000 individuals will be diagnosed with oral cancer. About 70 percent of these oral cancer diagnoses are found in late stages (stages three and four) and result in a startling five-year survival rate that is below 50 percent. Identifying these abnormalities earlier can raise the survival rate to as high as 90 percent. By making OralID® available to their patients, practitioners in the Aspen Dental network are helping break down barriers to oral cancer detection and getting patients access to screenings to encourage early stage oral cancer discovery.
“Forward Science believes that ‘we can defeat cancer; cancer will not defeat us,’” said Robert J. Whitman, Forward Science CEO. “Reaching millions of patients through the Aspen Dental branded network and encouraging early screening with the latest technology for oral cancer improves the odds of discovery in a treatable stage. We believe this partnership could change the trend in oral cancer impact for Americans.”
OralID was developed with the vision to create a simpler, more efficient, and more affordable oral cancer screening device. OralID® uses a proven, optically based “fluorescence technology” that aids in visualization of oral mucosal abnormalities. OralID® is distinct from other screening devices, because it is the only FDA-cleared device that can be used without any rinses, dyes, sheathes or barriers, limiting upfront or patient use-based costs.
“As the number of oral cancer cases rises annually, Aspen Dental teams play an increasingly critical role in early detection of potentially malignant lesions,” said Dr. Arwinder Judge, ADMI Chief Clinical Officer. “By partnering with Forward Science, practitioners across the Aspen Dental branded network can offer a truly comprehensive oral care exam that includes oral cancer screening, making it possible to detect patients’ treatment needs sooner, improving lifesaving outcomes.
Source: Company Press Release